Purpose: The goal of this study was to determine the specificity of 64 Cu-CB-TE2A-c(RGDyK) ( 64 Cu-RGD) for osteoclast-related diseases, such as Paget's disease or rheumatoid arthritis.
Introduction

B
one diseases are often accompanied by an increased number of osteoclasts, and osteolytic bone metastases are a significant cause of morbidity in many types of cancer. Increased osteoclastogenesis promotes osteolytic activity and bone loss, which can result in pain, pathologic fracture, spinal cord compression, and hypercalcemia [1, 2] . It has been reported that 30-85% of patients with metastatic breast cancer will develop metastatic bone lesions, which can be osteolytic, osteoblastic, or mixed in nature [2] . Importantly, micro-metastases are often associated with poor outcome in patients with small node-negative primary tumors [3] .
Osteoclasts are multinucleated cells of the macrophage/ monocyte lineage that uniquely function as the bone resorptive cells. Osteoclastogenesis is regulated by two cytokines from the tumor necrosis factor family of proteins: osteoprotegerin (OPG) and receptor activator of nuclear factor κB ligand (RANKL). Both cytokines are produced by the osteoblasts and influence bone remodeling by modulating the number of active osteoclasts. RANKL, through its interaction with RANK receptor, directs bone marrow macrophages to differentiate into active osteoclasts, while OPG, a decoy receptor for RANKL, negatively regulates RANKL's effect on macrophages [4] . In this context, the RANKL-OPG system provides a convenient way of manipulating the number of osteoclasts in vivo to model osteoclastogenesis.
Alpha v beta 3 (α V β 3 ) is the major integrin expressed by mature, active osteoclasts [5] . Integrin α V β 3 is a heterodimeric transmembrane glycoprotein which has been shown to play an important role in angiogenesis and tumor metastasis to the bone [6] . Consequently, α V β 3 has been evaluated as a potential site for therapeutic intervention. In addition, α V β 3 is the most abundant integrin on the surface of the osteoclast which makes it a useful imaging target for diseases resulting in increased osteoclast numbers [5] .
Imaging bone pathology has been a challenging undertaking. Both [7] [8] [9] [10] . However, 99m Tc-MDP and similar radiopharmaceuticals preferentially identify osteoblastic lesions [8] . 18 F-FDG uptake is increased in cells and tissues undergoing rapid division, growth, and inflammatory response. These processes are transient and are not necessarily tumor-specific [7, 11, 12] . Du et al. showed that 18 F-FDG was taken up in both osteolytic and osteoblastic lesions, with SUV max values correlating to the size of the tumor rather than whether the lesion was osteolytic or osteoblastic [10] . Consequently, these methods have shown poor effectiveness in imaging elevated numbers of osteoclasts associated with neoplastic metastatic activity in the bone. Imaging methods which rely on the bone density, such as x-ray or computed tomography (CT), are effective only when the bone tissue is significantly resorbed [9] . It is therefore clinically relevant to develop a method for imaging osteoclasts, which would be sensitive enough to detect the increases in cell numbers associated with osteolytic metastases.
Previous studies have shown that the Arg-Gly-Asp tripeptide (RGD) binds to α v β 3 with high affinity [13, 14] . Several linear and cyclic RGD-based ligands have been analyzed for their effectiveness at α v β 3 targeting [13] . These small molecules have better tumor-penetrating capacity than the much larger protein-based tracers, such as antibodies. Also, there is less chance of them being detected by the reticuloendothelial system and eliciting an immune response.
There are reports in the literature on the development and human studies of 18 F-labeled RGD agents for imaging tumor angiogenesis, specifically 18 F-galacto-RGD [15] [16] [17] [18] [19] . This agent has been investigated in human PET imaging trials in patients with breast, melanoma, head and neck cancer and glioma, and has demonstrated specific imaging of the α v β 3 integrin both in tumors and angiogenic blood vessels.
We reported on a cyclized version of RGD, c(RGDyK), conjugated to the cross-bridged chelator CB-TE2A (4,11- Cu has a half-life compatible with overnight shipping protocols and can be produced at a distant cyclotron site with high specific activity, making 64 Cu-CB-TE2A-c(RGDyK) (or 64 Cu-RGD) an attractive radiopharmaceutical. This compound has been shown to be highly effective as an osteoclast imaging agent in vivo in a pharmacological mouse model of direct administration of parathyroid-hormone into the calvarium [14] as well as in a mouse model of osteolytic bone metastasis [20] . As the 64 Culabeled RGD agent has already demonstrated uptake in osteoclasts, here, we used 64 Cu-RGD to visualize changes in osteoclast number in response to systemically administered OPG and RANKL. An imaging agent targeting osteoclasts, which are upregulated in osteolytic lesions, may facilitate earlier follow-up in patients with osteolytic or mixed bone metastases. Therapies for bone metastases include bisphospho- nates and the anti-RANKL antibody, denosumab, which inhibit the production of osteoclasts. The ability to image increased numbers of osteoclasts may also have significance for imaging and monitoring therapy of osteoporosis and rheumatoid arthritis (RA). 4%; E β−max , 573 keV) was produced on a biomedical cyclotron (CS-15; Cyclotron Corp.) at Washington University School of Medicine. CB-TE2A-c(RGDyK) was prepared as previously described [14] . All chemicals were purchased from SigmaAldrich (St. Louis, MO, USA), unless otherwise specified, and solutions were prepared using ultrapure water (18 MΩ-cm resistivity). Radiochemistry reaction progress and purity were monitored by analytical reversed-phase high-performance liquid chromatography (HPLC), which was performed on a Waters 600E chromatography system (Milford, MA, USA) with a Waters 991 photodiode array detector and an Ortec Model 661 radioactivity detector (EG&G Instruments, Oak Ridge, TN, USA). An Altima C18 Rocket® column was employed with a gradient that changes from 0.1% TFA in water to 30:70 0.1%TFA/water:0.1%TFA/CH 3 CN over the course of 5 min. In addition, radio-TLC was conducted on a Bioscan AR 2000 radio-TLC scanner equipped with a 10% methane/argon gas supply and a PC interface running Winscan v.3 analysis software. C-18 plates were employed using an eluent mixture of 3:7 10% NH 4 OAc/MeOH, and the complex 64 Cu(OAc) 2 as a standard control. Radioactive samples were counted using a Beckman 8000 (Franklin Lakes, NJ, USA) automated well-type gamma-counter. PET and CT data were acquired using either a microPET Focus 120 or a microPET Focus 220 and a microCAT II system, respectively (Siemens Medical Solutions, Knoxville, TN, USA).
Experimental
Methods and Materials
Animal Handling
Male C57BL/6 mice (5 weeks) were purchased from Charles River Laboratories, (Wilmington, MA, USA) and housed under pathogen-free conditions in an approved facility according to the guidelines of the Division of Comparative Medicine and the Animal Studies Committee of Washington University School of Medicine.
Radiochemistry
The complexation of 64 Cu to CB-TE2A-c(RGDyK) was achieved by reacting 2 μg (1.3×10 −3 μmol) of CB-TE2A-c (RGDyK), 118 μL solution of 0.1 M NH 4 OAc (pH=8.0) and 37 MBq (1,000 μCi) of 64 CuCl 2 in 0.1 N HCl for 1.5 h at 95°C. If needed, the reaction was further purified using a previously published method [21] . Purity was greater than 95% based upon radio-HPLC and radio-TLC analysis and the specific activities ranged from (11-37 MBq (300-1,000 μCi)/μg).
OPG and RANKL Treatment Protocol
Male C57BL/6 mice (∼23 g) were treated with OPG in doses of 0.2, 1.0, and 5.0 mg/kg dose in 100-μL saline twice a week for 2 weeks subcutaneously in the nape of the neck while under brief Isoflurane anesthesia. Control groups received saline according to the same schedule. Male C57BL/6 mice (∼23 g) were treated with RANKL in doses of 0.3 or 0.1 mg/kg (dose diluted in 50-μL saline) twice a day for 10 days subcutaneously in the nape of the neck while under brief isoflurane anesthesia.
Biodistribution
Biodistribution studies were conducted according to previously published protocols [14] . Briefly, on day 15(OPG) or day 11 (RANKL), treated and control mice were injected (IV, tail, heat, and restraint) with 20 μCi 
Blood Collection and Serum Tartrate-Resistant Acid Phosphatase (TRAP5b) Analysis
Blood samples from RANKL and OPG treated and control cohorts were collected by submandibular venous puncture before the biodistribution study or at the time of sacrifice. Serum was obtained by centrifuging the blood at 10,000 rpm for 5 min at 4°C in the serum separator tubes (Becton Dickinson; Franklin Lakes, NJ, USA) and stored at −20°C until use. A solid-phase immunoassay was used to measure osteoclastic TRAP5b activity. The MouseTRAP™ immunoassay kit was purchased from SBA Science/IDS Inc. (Fountain Hills, AZ, USA), and assays were performed according to the manufacturer's instructions.
Small Animal PET/CT Imaging
Male C57BL/6 mice (∼23 g) were treated with RANKL in doses of 0.3 mg/kg (dose diluted in 50-μL saline) twice a day for 10 days. On day 11, treated and control mice (n=4 for each group) were injected with 300 μCi 64 Cu-RGD (5.6-11.1 MBq) and imaged using small animal PET/CT 2, 4, and 24 h p.i., Co-registered images were re-constructed using the maximum a posteriori (MAP) algorithm [22] , and regions of interest (ROI) were determined from the co-registered PET/ CT images with AMIDE imaging software [23] . Standard uptake values (SUV) were determined as [(nanocurie per milliliter)×(animal weight (grams))/injected dose (nanocurie)]. Blood, lung, liver, muscle, kidney, spleen, leg bones, and tail were collected and counted for radioactivity for a post-imaging biodistribution.
Histology
After sacrifice from the biodistribution and the small animal imaging studies, the femur and tibia were removed, fixed in 10% formalin for 48 h, decalcified in a 14% EDTA solution replacing the buffer three times over a period of 14 days, embedded in paraffin, sectioned longitudinally at a thickness of 20 μm. Sections were stained with hematoxylin and eosin, and counterstained with TRAP to identify osteoclasts. Images were visualized under a Nikon Eclipse TE300 microscope equipped with a Plan Fluor 20/0.45 objective lens (Nikon) and MagnaFire digital charge-coupled device camera according to a standard protocol using the Osteomeasure Analysis System software (Osteometrics). The field of analysis included the entire tibia and femur, including cortical and trabecular bone. TRAP-positive osteoclasts were enumerated and divided by total bone tissue area.
Statistical Analysis
All data are presented as mean±SD. For statistical classification, a Student's t test (two-tailed, unpaired) was used to compare individual datasets. All statistical analyses were performed using PRISM software (GraphPad). P values less than 0.05 were considered significant.
Results
Decreased 64
Cu-CB-TE2A-c(RGDyK) PET Uptake in Bones with Reduced Osteoclast Numbers After OPG-Fc Administration Biodistribution studies after administration of PET imaging agent 64 Cu-RGD (Fig. 1) were performed on animals receiving a high (5 mg/kg twice a week for 2 weeks) dose of OPG and vehicle controls. Organs were harvested at appropriate times post-tracer administration and serum was collected for the TRAP5b level analysis. Although tracer accumulation in non-skeletal tissues of animals treated with 5 mg/mL of OPG-Fc was indistinguishable from vehicle control animals (Fig. 2a) , tracer accumulation in the leg bones of these animals was observed to be significantly less at 1 h post injection when compared to the control animals (OPG vs. saline;%ID/g, p value, 0.52±0.05 vs. 0.63±0.03, (Fig. 2b) . Serum TRAP5b is used as a measure of osteoclastogenesis and correlates with osteoclast number in bone [24] As expected, mice treated with 5 mg/kg OPG-Fc twice a week for 2 weeks had significantly decreased levels of serum TRAP5b (0.39±0.04 U/L) when compared to either the control mice (2.4±0.19 U/L) or mice prior to treatment (2.0±0.20 U/L) (Fig. 2c) . Taken together, these data demonstrate that 64 Cu-CB-TE2A-c(RGDyK) in bone was significantly lower in OPG-treated mice with decreased osteoclasts (as measured by serum TRAP5b and histology) compared to vehicle-treated mice.
Increased 64
Cu-CB-TE2A-c(RGDyK) Uptake in Bones with Increased Osteoclast Numbers After RANKL Administration Biodistribution of 64 Cu-RGD and serum TRAP5b levels were performed in mice administered 0.3 mg/kg RANKL twice a day for 10 days or vehicle control. After 10 days, mice injected with 64 Cu-RGD or saline were sacrificed at 1, 2, and 24 h post tracer injection and tracer biodistribution measured in bones and organs. Serum was collected for TRAP5b level determination.
The non-skeletal tissue biodistribution of 64 Cu-RGD assessed at 2 h after injection of the tracer did not vary significantly between the control and treated animals (Fig. 3a) . In contrast, the leg bones of mice treated with 0.3 mg/kg of RANKL showed an increase in the uptake of 64 Cu-RGD when compared to the bones from animals treated with saline at 1 and 2 h after injection of the tracer (Fig. 3a) . At 1 h post tracer injection, the bones from RANKL-treated animals retained 4.3 times more activity than the control mice, 3.8 vs. 0.88%ID/g. This differential increased to 7.5-fold at 2 h post tracer injection, 6.4 vs. 0.85%ID/g. The serum level of TRAP5b increased in RANKL-treated animals at both the 1-and 2-h time points (Fig. 3b) . 64 Cu-RGD uptake in the bone is depicted together with the serum TRAP5b data (Fig. 3b) .
Small Animal PET/CT Imaging Demonstrated Increased Tracer Uptake in Leg Bones of Animals Treated with RANKL
In experiments separate from the biodistribution studies, small animal PET/CT imaging was performed to evaluate Cu-RGD to accurately image and quantify osteoclast number in living animals treated with RANKL prior to imaging. A maximal intensity projection of a representative PET/CT image is shown in Fig. 4a . Increased uptake of the radiopharmaceutical was clearly visible in the femorotibial juncture of RANKL-treated animals when compared to animals treated with saline. SUVs obtained for RANKL-treated mice were 3.7 times higher than the SUV obtained from the control animals at 2 h after the tracer administration, with mean values being 0.12 (SE=0.02) and 0.03 (SE=0.02), respectively (Fig. 4b) , and correlated well with serum TRAP5b results, which indicated a significant 1.6-fold increase in RANKL-treated groups when compare to the control cohort (Fig. 4c) . SUVs obtained from scans performed 4 and 24 h after tracer administration did not show significant differences between the treated and the control groups, suggesting that the tracer was cleared from the bones at these later time points. After imaging, mice were sacrificed, leg bones were excised, de-calcified, stained for TRAP, and analyzed by histomorphometry. The microscopic evidence of the significant increase in osteoclast numbers can be seen in Fig. 5 . Figure 5a shows a femur from a RANKL-treated animal, demonstrating an increase in TRAP+ cells when compared to the femoral bone from a control animal, which is presented in Fig. 5b . Interestingly, bones from RANKL-treated animals were almost completely devoid of trabecular bone with the TRAP+ cells localized to the endosteal area. Histomorphometric analysis applied to the TRAP-stained sections demonstrated a 1.6-fold increase in the number of TRAP+ cells in bones of RANKL-treated animals ( Fig. 5d) , thus establishing the correlative relationship between osteoclast numbers and 64 Cu-RGD tracer uptake measured by small animal PET (Fig. 5e) .
Conversely, the femur from an OPG-Fc-treated mouse obtained from a biodistribution study exhibited a distinctive osteopetrotic phenotype characterized by an extended growth plate with abundant trabecular bone and severely decreased osteoclastogenesis (Fig. 5c) . Taken together, these data demonstrate that 64 Cu-RGD and small animal PET/CT was sensitive enough to detect increased uptake in bones of living mice with increased osteoclast number and decreased bone uptake in bones of mice with decreased OC number.
Discussion
In this report, we demonstrate the efficacy of 64 Cu-RGD radiotracer as a PET imaging agent of osteoclasts with potential applications in prognostication and staging of metastatic bone disease, or other osteoclast-related pathologies such as osteoporosis or RA, as well as for monitoring anti-osteoclast therapies. Bone tropism is a common characteristic of cancers originating in lung, breast, prostate, and thyroid gland [25, 26] . Metastatic complications of these malignancies are predominantly of an osteolytic etiology, and pathologically active osteoclastogenesis has been shown to be a valuable indicator for both diagnosis and therapy. For example, Roato et al. identified increased osteoclastogenesis as a prognosticative factor in non-small cell lung cancer (NSCLC) [27] . Bone metastasis from prostate cancer can create osteolytic, osteoblastic or mixed (lytic/blastic) lesions, and an osteoclast imaging modality capable of identifying patients with lytic or mixed lesions might help to tailor anti- resorptive therapies to those most likely to benefit from osteoclast inhibition. Osteolytic bone destruction is also a major factor in the pathophysiology of RA. In this case, a number of developing therapies act to restore the osteoclast/ osteoblast homeostasis [28] RA and NSCLC could clearly benefit from an assessment of in situ osteoclastogenesis. 64 Cu-RGD incorporates the cyclic c(RGDyK) moiety, a high-affinity ligand for α V β 3 , which is characteristically overexpressed on active osteoclasts [6] Numerous studies have established the α V β 3 integrin as an attractive target for molecular imaging of various pathologies [29] [30] [31] . Sprague et al. showed that locally induced osteoclastogenesis could be imaged with 64 Cu-RGD and PET [14] . This study also demonstrated the specificity of 64 Cu-RGD tracer using Western blotting and unlabeled tracer blocking techniques. Wadas et al. demonstrated the effectiveness of 64 Cu-RGD and small animal PET/CT in a mouse model of HTLV-1 adult T-cell leukemia (Tax+ transgenic) [20] . The data presented here extend these findings to demonstrate that a systemic modulation of osteoclastogenesis can be effectively imaged by 64 Cu-RGD and small animal PET/CT. Biodistribution studies were conducted to monitor the 64 Cu-RGD uptake in target and non-target tissues after systemic administration of osteoclastogenesis modulating cytokines OPG-Fc and RANKL. When the number of osteoclasts was increased by treatment with 0.3 mg/kg RANKL, the leg bones of treated animals retained on the average 4 to 7.5 times more 64 Cu-RGD than the bones of control animals ( Fig. 3) , while the uptake of 64 Cu-RGD in bones of control mice did not vary to any significant degree at all measured time points. Concomitant increase of TRAP5b levels in sera obtained from the RANKL-treated animals was consistent with an increase in bone resorption. This positive relationship suggested that 64 Cu-RGD uptake reflected active osteolysis by the target cell population. Inhibition of osteoclastogenesis with 5 mg/kg OPG-Fc resulted in modest, but statistically significant decreases in 64 Cu-RGD uptake in the leg bones of treated animals at 1 and 24 h post injection (Fig. 2) . Although this decrease in tracer uptake was statistically significant, it was only about 1.2-fold less than the uptake in a corresponding control. This differential uptake suggests that the sensitivity of PET imaging might not be sufficient enough to detect the inhibition of osteoclast activation. As the result, PET imaging studies were conducted only with RANKL-treated animals.
Sites of actively remodeling skeleton, such as upper and lower extremities and jaw bones, have been evaluated in previous studies that examined osteoclastogenesis [32] [33] [34] . Mouse leg bones were selected to study the imaging characteristics of 64 Cu-RGD for three reasons. Firstly, the leg bones are the sites of fairly active bone remodeling processes. Secondly, leg bones could be easily dissected and analyzed by both biodistribution and histomorphometry. Finally, leg bones are easy to evaluate in a post-imaging analysis, including the generation of ROI than such complex shapes as jaw bones. Small animal PET/CT imaging studies reflected the findings of the biodistribution experiments. When SUVs obtained from the PET images were analyzed, tracer accumulation in the target tissues of RANKL-treated animals was significantly higher 2 h after administration. The observed difference, about 3.7-fold, correlated well with previously reported data [14, 20] Histological analysis conducted on the bones of RANKL-treated animals confirmed the expected increase in osteoclast number, suggesting that the SUV differential is due to the enhanced osteoclastogenesis. SUVs obtained from scans performed 4 and 24 h after tracer administration did not show significant differences between the treated and the control groups, possibly due to the internalization and subsequent redistribution of the tracer throughout the reticuloendothelial system, as demonstrated by the uptake in liver and gut.
Although the data demonstrate clear correlations between pharmacological treatment, bone associated activity and osteoclast number, variability in the data is observed (Fig. 3) , which may be associated with inter-mouse variation in response to the RANKL treatment regimen. Walsh et al. noted that that pharmacologic modulation leads to variable responses within a cohort of study animals [35] . This may be due in part to the microfractures caused by a significant influx of active osteoclasts resulting in loss of bone tissue during the extraction associated with the biodistribution procedure. Furthermore, PET imaging and serum TRAP5b level assessment, modalities that do not involve potentially damaging post-mortem tissue extraction, demonstrate much less inter-experimental variability than the biodistribution modality. We anticipate that earlier time points after the initiation of RANKL injections would have yielded greater overall osteoclast numbers, fewer or no microfractures, and a potentially greater accumulation of tracer.
TRAP5b is a well-established marker for osteoclast number; however, it represents the contribution of not only osteoclasts, but also immature precursor cells [36] . These cells likely do not overexpress α v β 3 integrin and, therefore, will not be targeted by 64 Cu-RGD. For these reasons, a direct correlation between the serum levels of TRAP5b and the SUV obtained from the PET images is not established here; rather TRAP5b was used to independently demonstrate the effects of OPG and RANKL in our system. Additionally, TRAP5b is a system serum marker that will monitor the level of osteoclasts and precursors throughout the mouse skeleton, whereas in the biodistribution and imaging studies, only the knee joints were monitored for level of uptake of 64 Cu-RGD. In order to establish whether the tracer uptake in the bone reflects the number of mature osteoclasts, histomorphometry studies were conducted (Fig. 5d, e) , which demonstrate a positive correlation between the number of mature osteoclasts and the tracer uptake in the bone.
Conclusion
This report describes the evaluation of 64 Cu-RGD as a biomarker for osteoclast number associated with increased osteoclastogenesis. We demonstrated that the uptake of this radiotracer accurately reflected both osteopetrotic and osteoporotic phenotypes in biodistribution studies supported by the serum TRAP5b levels. Small-animal PET studies supported by biodistribution and histological analyses demonstrated that 64 Cu-RGD was capable of imaging an increase in osteoclastogenesis typically associated with pathologically active bone resorption in vivo. Overall, these data establish 64 Cu-RGD as a potentially effective imaging agent for the detection of pathologies associated and accompanied by an increase in osteoclast number. Since 64 Cu-RGD targets the α V β 3 integrin, its use can also be extended to imaging of metastases formed by α V β 3 -bearing tumors.
